Sign In
Buy LLY
$1,131.42
+6.15 (+0.547%)
At Close: Jun 05, 2026
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
10:15am, Tuesday, 17'th Sep 2024
A huge opportunity in healthcare today is treatment of patients for diabetes and obesity. Another emerging area with limited competition is treating Alzheimer's disease.
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
10:06am, Tuesday, 17'th Sep 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
05:21am, Tuesday, 17'th Sep 2024
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Radioactive cancer technology: New billion dollar opportunity?
09:33am, Monday, 16'th Sep 2024
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna
03:00am, Sunday, 15'th Sep 2024
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.
3 Stocks to Buy and Hold Forever
07:30am, Saturday, 14'th Sep 2024
AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
US FDA approves Eli Lilly's eczema drug
04:17pm, Friday, 13'th Sep 2024
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin clear
Calls of the Day: Vistra, Garmin, Tesla and Eli Lilly
01:08pm, Friday, 13'th Sep 2024
The Investment Committee discuss the latest Calls Of The Day.
Citi resumes coverage of Eli Lily with a Buy rating: Should you invest?
11:03am, Friday, 13'th Sep 2024
Citi has resumed coverage of Eli Lilly & Co. (NYSE: LLY) with a “Buy” rating, setting a price target of $1,060 per share—implying a potential 13% upside from the current stock price.
6 Incredible Reasons to Invest in Eli Lilly
08:45am, Friday, 13'th Sep 2024
The pharma giant's financial results have been strong, largely thanks to its new crown jewel. But there may be more to come as the company's development pipeline looks incredibly exciting.
Eli Lilly Invests $1.8B To Expand Drug Output in Ireland
05:01pm, Thursday, 12'th Sep 2024
Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's treat
Healthcare Stocks Have Popped. Consider These 2 That Haven't.
03:32pm, Thursday, 12'th Sep 2024
Money has poured into the sector as markets have grown concerned about the economy.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
11:50am, Thursday, 12'th Sep 2024
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Five Top Obesity Stocks to Buy and Hold Long Term
11:50am, Thursday, 12'th Sep 2024
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
